Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* All adult patients (\>18 years of age)~* Patients undergoing standard or reverse total shoulder arthroplasty for the primary diagnoses of glenohumeral arthritis or cuff tear arthropathy~* Cognitively intact with the ability to give informed consent as outlined by our institutional review board.~* Patients must be capable of participating in the post-operative electronic survey and / or able to maintain a written diary of events~Exclusion Criteria~* Non-elective cases~* Infection, tumor, trauma~* Weight \< 50 kg~* Patients with any contraindications to regional anesthesia including allergy or hypersensitivity to amide-type local anesthetics~* Patients with allergy to any component of medication regimen e.g. amide- type local anesthetics, oxycodone, hydromorphone, fentanyl~* Chronic pain patients with history of chronic opioid use (defined as 20 mg morphine equivalent / day for greater than 30 days pre-operatively~* Concurrent painful physical condition that may require analgesic treatment that is not related to the shoulder surgery (chronic peripheral neuropathy, radiculopathy, or other neurologic disorder)~* Severe hepatic disease defined by clinical evidence of liver disease with abnormal liver function tests.~* Pregnancy~* Respiratory disease that contraindicates interscalene nerve block (elevated contralateral hemidiaphragm, contralateral pneumonectomy, or severe COPD with FEV1 \< 50% predicted, and 02 dependence)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine (Type: EXPERIMENTAL): Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
- Plain Bupivacaine (Type: ACTIVE_COMPARATOR): Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.

Based on this trial design, predict the completion outcome and termination type (if applicable).